000998 隆平高科
2025/03 - 三个月
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入1,408,513-32.03%8,565,5539,223,2177,532,0713,503,442
减:营业总成本1,322,242-34.97%8,932,5898,569,1027,301,8913,410,685
    其中:营业成本838,187-33.91%5,432,0345,555,7204,607,5882,302,758
               财务费用(55,121)-146.42%855,958397,896476,443100,341
               资产减值损失(2,084)-76.85%(387,213)(243,571)(451,484)(450,213)
公允价值变动收益(41,764)956.69%41,466(103,153)(16,437)11,338
投资收益(2,707)-224.44%263,514(39,125)(21,233)583,300
    其中:对联营企业和合营企业的投资收益(4,410)407.04%(21,374)(52,442)(90,283)118,784
营业利润75,89148.51%(373,150)362,550(270,011)215,761
利润总额76,21558.98%(370,487)361,510(295,037)190,854
减:所得税费用44,379-227.09%(209,865)(12,038)137,33917,674
净利润31,836-61.58%(160,622)373,549(432,376)173,180
减:非控股权益33,930467.83%(274,488)173,494400,493110,733
股东净利润(2,095)-102.72%113,867200,055(832,869)62,447

市场价值指针
每股收益 (元) *-0.002-102.74%0.0900.150-0.6400.050
每股派息 (元) *----0.0400.050----
每股净资产 (元) *3.807-10.34%3.6224.2573.8254.181
审计意见 #--标准无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容